In addition, by using a preclinical model of breast cancer, previous studies demonstrated that over-expression of HER2 leads to increasing cross-talk between ER and HER2 pathways, even if the mechanism of the influence between ER and HER2 remains unclear [24, 25]. The gene discussed is ERBB2; the disease is breast carcinoma.